News
Endo is taking advantage of June’s status as Men’s Health Month to encourage men to prioritize their physical, mental and ...
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...
Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...
Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...
In the latest episode of The Top Line podcast, host Heath Clendenning interviews Cheryl Lubbert, CEO of Reverba Global, to ...
In a recent interview with Fierce, Brie Thomas, senior vice president of sales at Swoop, shared insights on the dramati | ...
EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS | Embrace the transformative power of multimodal ...
AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...
In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...
With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...
Hey, AbbVie, what do you say? The Cubs are gonna strike out cancer today. | A new partnership between the Chicago-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results